Last updated: February 19, 2026
Vybrique, also known by its generic name Lorviqua (lorlatinib), is a targeted therapy used primarily for treating specific types of lung cancer (non-small cell lung cancer with ALK or ROS1 mutations). The drug is marketed by Pfizer Inc.
Manufacturing and Supply Chain Overview
Understanding the supply chain for Vybrique involves identifying key suppliers across different stages:
1. Active Pharmaceutical Ingredient (API) Suppliers
The core component of Vybrique is lorlatinib, which requires high-purity chemical synthesis.
-
Pfizer's API sourcing: Pfizer manages its API production through internal manufacturing facilities or approved external contract manufacturing organizations (CMOs). The company does not publicly disclose all API suppliers but indicates use of multiple CMOs to ensure supply security.
-
Key API manufacturers (industry estimates): Several companies globally produce APIs for kinase inhibitors similar to lorlatinib:
| Company |
Location |
Capabilities |
| Samsung Biologics |
South Korea |
CMO for small-molecule APIs |
| WuXi AppTec |
China |
API manufacturing for oncology drugs |
| Lonza |
Switzerland |
Custom synthesis, including complex APIs |
2. Contract Manufacturing Organizations (CMOs)
Pfizer sources parts of its supply chain from specialized CMOs:
-
WuXi AppTec: Manufactures APIs and intermediates, especially for kinase inhibitors.
-
Samsung Biologics: Produces formulations and performs fill-finish processes.
-
Veristat and Patheon (Thermo Fisher): Contracted for Drug Product manufacturing and fill-finish supplies.
3. Raw Material Suppliers
Raw chemicals and intermediates for lorlatinib synthesis are sourced from chemical suppliers with strict quality and regulatory standards:
Supply Chain Factors
-
Regulations and Quality Control: Suppliers must adhere to cGMP standards to meet FDA and EMA regulations.
-
Supply Risk: Dependence on a limited number of API suppliers presents risks of disruptions due to geopolitical issues, raw material shortages, or manufacturing delays.
-
Active Monitoring: Pfizer and authorized distributors actively monitor supply levels and stability through global logistics networks to ensure consistent drug availability.
Key Market Participants
- Pfizer Inc.: Owns the brand Vybrique, manages global supply.
- Contract Manufacturers and Raw Material Suppliers: Critical for production continuity.
- Regulatory Authorities: Include U.S. FDA, EMA, and other local agencies, oversee manufacturing compliance.
Summary of Major Supply Chain Players
| Segment |
Key Companies |
Role |
| API Production |
WuXi AppTec, Samsung Biologics, Lonza |
Manufacturing lorlatinib API |
| Formulation and Fill-Finish |
Patheon, Samsung Biologics |
Completing drug product manufacturing |
| Raw Chemicals |
Sigma-Aldrich, TCI Chemicals |
Suppliers of intermediates and reagents |
Market Dynamics and Trends
- Rising demand for targeted cancer therapies increases pressure on supply chains.
- Pfizer's utilization of multiple CMOs reduces single-source dependency.
- Increasing regulatory scrutiny urges transparency and diversification in supplier selection.
Final Note
Specific supplier names for Vybrique are generally not publicly disclosed in detail due to confidentiality agreements. The supply chain comprises Pfizer's internal manufacturing, external CMOs, and raw chemical suppliers tested for compliance and capacity.
Key Takeaways
- Pfizer controls the primary manufacturing of Vybrique, with API production likely involving multiple CMOs.
- External suppliers include WuXi AppTec, Samsung Biologics, and raw chemical providers such as Sigma-Aldrich.
- Dependencies on limited suppliers pose supply risks, prompting diversification efforts.
- Regulatory standards influence supplier choices and manufacturing practices within the supply chain.
Frequently Asked Questions
1. Who manufactures the active ingredient lorlatinib?
While Pfizer owns the drug, specific API manufacturing sites are not publicly disclosed. They likely source lorlatinib from approved CMOs like WuXi AppTec or Samsung Biologics.
2. Which companies supply raw chemicals for lorlatinib synthesis?
Suppliers include Sigma-Aldrich and TCI Chemicals, providing specialty reagents and intermediates.
3. How does Pfizer ensure supply chain stability?
Pfizer employs multiple CMOs, maintains safety stock, and adheres to cGMP standards; continuous monitoring mitigates disruptions.
4. Are there risks in the current supply chain?
Yes, reliance on key CMOs and raw material suppliers introduces supply chain risks, which Pfizer aims to reduce through diversification.
5. Can new suppliers be added in response to shortages?
Yes, Pfizer has the flexibility to onboard additional CDMOs and raw material sources as needed to meet demand.
References
[1] Pfizer. (2022). Vybrique (lorlatinib) prescribing information.
[2] Industry reports. (2022). Global API manufacturing and supply chain analysis.
[3] U.S. FDA. (2022). cGMP guidelines for pharmaceutical manufacturing.
[4] TCI Chemicals. (2022). Specialty chemicals for pharmaceutical synthesis.
[5] Sigma-Aldrich. (2022). Reagents for drug synthesis.
